JP2019508433A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019508433A5 JP2019508433A5 JP2018546036A JP2018546036A JP2019508433A5 JP 2019508433 A5 JP2019508433 A5 JP 2019508433A5 JP 2018546036 A JP2018546036 A JP 2018546036A JP 2018546036 A JP2018546036 A JP 2018546036A JP 2019508433 A5 JP2019508433 A5 JP 2019508433A5
- Authority
- JP
- Japan
- Prior art keywords
- liv
- adc
- subject
- pharmaceutical composition
- drug conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022006944A JP2022058676A (ja) | 2016-03-15 | 2022-01-20 | Ｌｉｖ１－ａｄｃ及び化学療法剤を用いた併用療法 |
| JP2024039750A JP2024075639A (ja) | 2016-03-15 | 2024-03-14 | Ｌｉｖ１－ａｄｃ及び化学療法剤を用いた併用療法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662308639P | 2016-03-15 | 2016-03-15 | |
| US62/308,639 | 2016-03-15 | ||
| US201662317792P | 2016-04-04 | 2016-04-04 | |
| US62/317,792 | 2016-04-04 | ||
| US201662367510P | 2016-07-27 | 2016-07-27 | |
| US62/367,510 | 2016-07-27 | ||
| PCT/US2017/022541 WO2017161007A1 (en) | 2016-03-15 | 2017-03-15 | Combination therapy using a liv1-adc and a chemotherapeutic |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022006944A Division JP2022058676A (ja) | 2016-03-15 | 2022-01-20 | Ｌｉｖ１－ａｄｃ及び化学療法剤を用いた併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019508433A JP2019508433A (ja) | 2019-03-28 |
| JP2019508433A5 true JP2019508433A5 (enExample) | 2020-04-23 |
Family
ID=59852409
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018546036A Pending JP2019508433A (ja) | 2016-03-15 | 2017-03-15 | Ｌｉｖ１−ａｄｃ及び化学療法剤を用いた併用療法 |
| JP2022006944A Pending JP2022058676A (ja) | 2016-03-15 | 2022-01-20 | Ｌｉｖ１－ａｄｃ及び化学療法剤を用いた併用療法 |
| JP2024039750A Pending JP2024075639A (ja) | 2016-03-15 | 2024-03-14 | Ｌｉｖ１－ａｄｃ及び化学療法剤を用いた併用療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022006944A Pending JP2022058676A (ja) | 2016-03-15 | 2022-01-20 | Ｌｉｖ１－ａｄｃ及び化学療法剤を用いた併用療法 |
| JP2024039750A Pending JP2024075639A (ja) | 2016-03-15 | 2024-03-14 | Ｌｉｖ１－ａｄｃ及び化学療法剤を用いた併用療法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11325980B2 (enExample) |
| EP (1) | EP3429626A4 (enExample) |
| JP (3) | JP2019508433A (enExample) |
| KR (3) | KR20220157515A (enExample) |
| CN (1) | CN108697801A (enExample) |
| AU (2) | AU2017235545A1 (enExample) |
| BR (1) | BR112018068129A2 (enExample) |
| CA (1) | CA3016485A1 (enExample) |
| EA (1) | EA201891968A1 (enExample) |
| IL (1) | IL261505A (enExample) |
| MA (1) | MA45324A (enExample) |
| MX (2) | MX2018010847A (enExample) |
| SG (2) | SG10201912908QA (enExample) |
| WO (1) | WO2017161007A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX379481B (es) | 2010-12-06 | 2025-03-11 | Seagen Inc | Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer |
| KR20200090838A (ko) * | 2017-12-01 | 2020-07-29 | 시애틀 지네틱스, 인크. | 유방암 치료를 위한 인간화된 항-liv1 항체 |
| CN113015750A (zh) | 2018-11-07 | 2021-06-22 | 克里斯珀医疗股份公司 | 抗liv1免疫细胞癌症疗法 |
| TW202133887A (zh) * | 2019-12-09 | 2021-09-16 | 美商西健公司 | 使用liv1-adc及pd-1拮抗劑之組合療法 |
| CA3197158A1 (en) * | 2020-09-28 | 2022-03-31 | Seagen Inc. | Humanized anti-liv1 antibodies for the treatment of cancer |
| KR20230158005A (ko) | 2021-03-18 | 2023-11-17 | 씨젠 인크. | 생물학적 활성 화합물의 내재화된 접합체로부터의 선택적 약물 방출 |
| EP4682168A1 (en) * | 2023-03-15 | 2026-01-21 | BioRay Pharmaceutical Co., Ltd. | Anti-liv-1 antibody and anti-liv-1 antibody-drug conjugate, and pharmaceutical use thereof |
| WO2025162207A1 (zh) * | 2024-01-31 | 2025-08-07 | 上海复宏汉霖生物技术股份有限公司 | 抗liv1抗体及使用方法 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Acylhydrazone derivatives of anthracycline and methods for their preparation |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ES2129454T3 (es) | 1991-08-22 | 1999-06-16 | Becton Dickinson Co | Procedimientos y composiciones de tratamientos de cancer y pronostico de reacciones a los indicados tratamientos. |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| CA2132500A1 (en) | 1994-09-20 | 1996-03-21 | David Lockwood Manning | Methods for predicting the behaviour of breast tumours |
| ATE234635T1 (de) | 1995-12-22 | 2003-04-15 | Bristol Myers Squibb Co | Verzweigte hydrazongruppen enthaltende kuppler |
| US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
| WO1998018945A1 (en) | 1996-10-31 | 1998-05-07 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the breast |
| US6066778A (en) | 1996-11-06 | 2000-05-23 | The Regents Of The University Of Michigan | Transgenic mice expressing APC resistant factor V |
| WO1998034118A1 (en) | 1997-01-30 | 1998-08-06 | Yale University | Diagnostic methods and compositions based on the distribution of rad51 |
| EP1027444A1 (en) | 1997-10-31 | 2000-08-16 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the breast |
| WO1999025877A1 (en) | 1997-11-18 | 1999-05-27 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the breast |
| EP1042360A2 (en) | 1997-12-24 | 2000-10-11 | Corixa Corporation | Compounds for immunotherapy and diagnosis of breast cancer and methods for their use |
| JP3422776B2 (ja) | 1998-08-04 | 2003-06-30 | ダイアデクスアス・インコーポレーテッド | 乳癌を診断、監視、病期決定、造影及び治療する新規な方法 |
| ATE386804T1 (de) | 1998-10-15 | 2008-03-15 | Novartis Vaccines & Diagnostic | Gene mit veränderter expression in metastatischen brust- oder dickdarm- krebszellen |
| AU3395900A (en) | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
| US20040141983A1 (en) | 1999-03-15 | 2004-07-22 | Protein Design Labs, Inc. | Compositions against cancer antigen LIV-1 and uses thereof |
| US6762020B1 (en) | 1999-03-15 | 2004-07-13 | Protein Design Labs, Inc. | Methods of diagnosing breast cancer |
| US7285382B2 (en) | 2000-01-25 | 2007-10-23 | Genentech, Inc. | Compositions and methods for treatment of cancer |
| AU2001264099A1 (en) | 2000-06-13 | 2001-12-24 | University College Cardiff Consultants Ltd. | Zinc transporters |
| US6964849B2 (en) | 2001-01-11 | 2005-11-15 | Curagen Corporation | Proteins and nucleic acids encoding same |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| WO2003000012A2 (en) | 2001-06-21 | 2003-01-03 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer |
| AU2002322280A1 (en) | 2001-06-21 | 2003-01-21 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| KR101104655B1 (ko) | 2002-03-08 | 2012-01-13 | 애보트 바이오테라퓨틱스 코포레이션 | 암 항원 ｔｍｅｆｆ２ 에 대한 항체 및 이의 용도 |
| DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
| MXPA05007940A (es) | 2003-01-27 | 2007-06-14 | Biogen Idec Inc | Composiciones y metodos para el tratamiento del cancer usando igsf9 y liv-1. |
| WO2004067564A2 (en) | 2003-01-29 | 2004-08-12 | Protein Design Labs, Inc. | Compositions against cancer antigen liv-1 and uses thereof |
| CN107213469A (zh) | 2003-11-06 | 2017-09-29 | 西雅图基因公司 | 能够与配体偶联的单甲基缬氨酸化合物 |
| US7371381B2 (en) | 2003-12-12 | 2008-05-13 | Amgen Inc. | Anti-galanin antibodies and uses thereof |
| US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| US20060222653A1 (en) | 2004-11-12 | 2006-10-05 | Xencor, Inc. | Antibodies operably linked to selected chemoattractants |
| WO2006124269A2 (en) | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
| CN101309933A (zh) * | 2005-09-07 | 2008-11-19 | 米迪缪尼有限公司 | 毒素偶联的Eph受体抗体 |
| AU2006287416A1 (en) * | 2005-09-07 | 2007-03-15 | Medimmune, Llc | Toxin conjugated Eph receptor antibodies |
| EP2012827A2 (en) | 2006-04-13 | 2009-01-14 | Novartis Vaccines and Diagnostics, Inc. | Methods of treating, diagnosing or detecting cancer |
| DK2099823T4 (da) | 2006-12-01 | 2022-05-09 | Seagen Inc | Målbindingsmiddelvarianter og anvendelser deraf |
| JP2010527916A (ja) | 2007-04-23 | 2010-08-19 | ワイス・エルエルシー | Ｉｌ−１３関連障害を治療する方法および組成物ならびにその治療をモニターする方法 |
| EP2641919A3 (en) | 2007-11-30 | 2014-05-07 | Glaxo Group Limited | Antigen-binding constructs |
| RU2011101378A (ru) | 2008-06-16 | 2012-07-27 | Сайвидон Дайагностикс Гмбх (De) | Алгоритмы предсказания исхода у пациентов с узловой формой рака молочной железы после химиотерапии |
| WO2010045234A1 (en) | 2008-10-14 | 2010-04-22 | University Of Louisville Research Foundation, Inc. | Methods of optimizing treatment of estrogen-receptor positive breast cancers |
| WO2010069858A1 (en) | 2008-12-19 | 2010-06-24 | F. Hoffmann-La Roche Ag | Pharmaceutical composition |
| US8642270B2 (en) | 2009-02-09 | 2014-02-04 | Vm Institute Of Research | Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer |
| US20110165566A1 (en) | 2009-07-09 | 2011-07-07 | Wittliff James L | Methods of optimizing treatment of breast cancer |
| CN102597268B (zh) | 2009-09-03 | 2017-09-22 | 弗·哈夫曼-拉罗切有限公司 | 用于治疗、诊断和监控类风湿性关节炎的方法 |
| MX379481B (es) | 2010-12-06 | 2025-03-11 | Seagen Inc | Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer |
| WO2012125712A2 (en) | 2011-03-14 | 2012-09-20 | Respira Health, Llc | Lung tumor classifier for current and former smokers |
| MY194408A (en) | 2011-10-14 | 2022-11-30 | Genentech Inc | Uses for and Article of Manufacture Including Her2 Dimerization Inhibitor Pertuzumab |
| CA2873111A1 (en) * | 2012-05-11 | 2013-11-14 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of bispecific scfv conjugates in combination with anti-cancer therapeutics |
| DE202012006349U1 (de) | 2012-07-03 | 2013-07-05 | Schuster Engineering Gmbh | Schiffsladeanordnung |
| KR101645905B1 (ko) * | 2012-10-12 | 2016-08-04 | 스피로즌 살 | 피롤로벤조디아제핀 및 그의 컨주게이트 |
| WO2015002134A1 (ja) * | 2013-07-02 | 2015-01-08 | 公益財団法人がん研究会 | 細胞性免疫誘導ワクチン |
| US11185594B2 (en) | 2014-04-10 | 2021-11-30 | Daiichi Sankyo Company, Limited | (Anti-HER2 antibody)-drug conjugate |
| KR20200090838A (ko) * | 2017-12-01 | 2020-07-29 | 시애틀 지네틱스, 인크. | 유방암 치료를 위한 인간화된 항-liv1 항체 |
| CN113015750A (zh) | 2018-11-07 | 2021-06-22 | 克里斯珀医疗股份公司 | 抗liv1免疫细胞癌症疗法 |
| GB201908208D0 (en) | 2019-06-10 | 2019-07-24 | Univ College Cardiff Consultants Ltd | An anti-mitotic agent |
| TW202133887A (zh) | 2019-12-09 | 2021-09-16 | 美商西健公司 | 使用liv1-adc及pd-1拮抗劑之組合療法 |
-
2017
- 2017-03-15 KR KR1020227039721A patent/KR20220157515A/ko not_active Ceased
- 2017-03-15 BR BR112018068129A patent/BR112018068129A2/pt active Search and Examination
- 2017-03-15 MA MA045324A patent/MA45324A/fr unknown
- 2017-03-15 KR KR1020237041743A patent/KR20230169462A/ko not_active Withdrawn
- 2017-03-15 SG SG10201912908QA patent/SG10201912908QA/en unknown
- 2017-03-15 WO PCT/US2017/022541 patent/WO2017161007A1/en not_active Ceased
- 2017-03-15 CN CN201780013873.8A patent/CN108697801A/zh active Pending
- 2017-03-15 KR KR1020187028273A patent/KR20180121571A/ko not_active Ceased
- 2017-03-15 AU AU2017235545A patent/AU2017235545A1/en not_active Abandoned
- 2017-03-15 SG SG11201807526SA patent/SG11201807526SA/en unknown
- 2017-03-15 MX MX2018010847A patent/MX2018010847A/es unknown
- 2017-03-15 CA CA3016485A patent/CA3016485A1/en active Pending
- 2017-03-15 EP EP17767448.8A patent/EP3429626A4/en not_active Withdrawn
- 2017-03-15 JP JP2018546036A patent/JP2019508433A/ja active Pending
- 2017-03-15 EA EA201891968A patent/EA201891968A1/ru unknown
- 2017-03-15 US US16/085,511 patent/US11325980B2/en active Active
-
2018
- 2018-09-02 IL IL261505A patent/IL261505A/en unknown
- 2018-09-07 MX MX2023008849A patent/MX2023008849A/es unknown
-
2022
- 2022-01-20 JP JP2022006944A patent/JP2022058676A/ja active Pending
- 2022-10-17 US US18/047,243 patent/US20230235083A1/en not_active Abandoned
-
2024
- 2024-03-14 JP JP2024039750A patent/JP2024075639A/ja active Pending
- 2024-03-21 AU AU2024201856A patent/AU2024201856A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019508433A5 (enExample) | ||
| Glassman et al. | Mechanistic considerations for the use of monoclonal antibodies for cancer therapy | |
| Liao et al. | Model‐informed therapeutic dose optimization strategies for antibody–drug conjugates in oncology: what can we learn from US Food and Drug Administration–approved antibody–drug conjugates? | |
| JP6177133B2 (ja) | Ｃｄ３８を特異的に認識する抗体とボルテゾミブを含有する抗腫瘍性の組合せ | |
| Koga et al. | Antitumor effect of antitissue factor antibody‐MMAE conjugate in human pancreatic tumor xenografts | |
| PH12019502484A1 (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| US20230235083A1 (en) | Combination therapy using a liv1-adc and a chemotherapeutic | |
| JP2018522850A5 (enExample) | ||
| JP2019516748A5 (enExample) | ||
| RU2016148927A (ru) | Лечение рака легкого с помощью комбинации антитела против pd-1 и другого противоракового средства | |
| JP2019503387A5 (enExample) | ||
| JP2016520082A5 (enExample) | ||
| HRP20151172T1 (hr) | Sastavi i postupci za dijagnosticiranje i lijeäśenje raka | |
| JP2019517505A5 (enExample) | ||
| CA3093731A1 (en) | Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor | |
| JP2021501776A5 (enExample) | ||
| CA3150274A1 (en) | Treatment of cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins | |
| WO2011101328A3 (en) | Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor | |
| JP2019524713A5 (enExample) | ||
| CN102448497A (zh) | 在癌症治疗中的西仑吉肽的持续给药 | |
| KR20210084560A (ko) | Pd-1/pd-l1 신호전달 억제제에 반응하지 않는 암을 치료하기 위한 방법 및 약제 | |
| Chakraborty et al. | A phase 1, open-label, dose-escalation study of the safety and efficacy of anti-CD38 antibody drug conjugate (STI-6129) in patients with relapsed or refractory multiple myeloma | |
| Pretelli et al. | Antibody-drug conjugates combinations in cancer treatment | |
| Hu et al. | Review of dose justifications for antibody-drug conjugate approvals from clinical pharmacology perspective: a focus on exposure-response analyses | |
| Richardson et al. | Antibody drug conjugates in the treatment of epithelial ovarian cancer |